TNB Financial increased its position in shares of Shire PLC (NASDAQ:SHPG) by 5.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,204 shares of the biopharmaceutical company’s stock after buying an additional 1,188 shares during the period. TNB Financial’s holdings in Shire PLC were worth $3,505,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in the stock. Heritage Investors Management Corp raised its stake in shares of Shire PLC by 11.8% in the first quarter. Heritage Investors Management Corp now owns 21,793 shares of the biopharmaceutical company’s stock worth $3,797,000 after buying an additional 2,295 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in shares of Shire PLC during the first quarter worth $662,000. Private Trust Co. NA raised its stake in shares of Shire PLC by 39.7% in the first quarter. Private Trust Co. NA now owns 3,929 shares of the biopharmaceutical company’s stock worth $684,000 after buying an additional 1,117 shares during the last quarter. Bremer Trust National Association bought a new stake in shares of Shire PLC during the first quarter worth $355,000. Finally, Capstone Asset Management Co. raised its stake in shares of Shire PLC by 7.3% in the first quarter. Capstone Asset Management Co. now owns 32,782 shares of the biopharmaceutical company’s stock worth $5,712,000 after buying an additional 2,237 shares during the last quarter. 21.06% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Shire PLC (NASDAQ SHPG) traded up 0.31% on Monday, hitting $163.74. 1,497,731 shares of the stock traded hands. Shire PLC has a 52-week low of $158.88 and a 52-week high of $209.22.
Shire PLC (NASDAQ:SHPG) last released its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 EPS for the quarter, topping analysts’ consensus estimates of $3.22 by $0.41. The company had revenue of $3.57 billion during the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The firm’s revenue for the quarter was up 109.0% on a year-over-year basis. During the same quarter last year, the business earned $2.12 earnings per share. Analysts expect that Shire PLC will post $14.88 earnings per share for the current fiscal year.
WARNING: This article was reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/2723478/shire-plc-nasdaqshpg-shares-bought-by-tnb-financial.html.
A number of equities research analysts have recently weighed in on the stock. HSBC Holdings plc lowered shares of Shire PLC from a “hold” rating to a “reduce” rating in a research note on Friday, May 19th. Royal Bank Of Canada set a $221.00 target price on shares of Shire PLC and gave the company a “buy” rating in a research note on Thursday, May 18th. Sanford C. Bernstein lowered shares of Shire PLC from an “outperform” rating to a “market perform” rating and cut their target price for the company from $209.22 to $161.09 in a research note on Thursday, May 25th. BidaskClub raised shares of Shire PLC from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. Finally, ValuEngine lowered shares of Shire PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and sixteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $227.45.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.